An international multicenter observational non-interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT)

References

• Romero R, Bonet J, de la Sierra A, et al. Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press. 2007;16(6):347–353.
   PubMed Web of Science ®Google Scholar
• Kotsis V, Jordan J, Micic D, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. J Hypertens. 2018;36(7):1427–1440.
   PubMed Web of Science ®Google Scholar
• Wong D, Lopez V, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med. 2007;167(22):2431–2436.
   PubMedGoogle Scholar
• Wilson PWF, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162(16):1867–1872.
   PubMedGoogle Scholar
• Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27(8):479–486.
   PubMed Web of Science ®Google Scholar
• Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring: comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan. J Clin Hypertens. 2011;13(7):467–472.
   Web of Science ®Google Scholar
• White WB, Cuadra RH, Lloyd E, et al. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016;34(4):788–797.
   PubMed Web of Science ®Google Scholar
• White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413–420.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81–88.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of effectiveness of azilsartan medoxomil and olmesartan in blacks versus whites with systemic hypertension. Am J Cardiol. 2018;122(9):1496–1505.
   PubMed Web of Science ®Google Scholar
• Rakugi H, Enya K, Sugiura K, et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35(5):552–558.
   PubMed Web of Science ®Google Scholar
• Takagi H, Mizuno Y, Niwa M, et al. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37(5):432–437.
   PubMed Web of Science ®Google Scholar
• Gitt AK, Bramlage P, Potthoff SA, et al. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016;16(1):56.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14–26.
   PubMed Web of Science ®Google Scholar
• Boytsov SA, Balanova YA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ESSE RF. Cardiovasc Ther Prev. 2014;13(4):4–14.
   Google Scholar
• Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis. 2004;47(2):105–115.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310–318.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Asakura M, Nakano A, et al. Azilsartan, but not candesartan improves left ventricular diastolic function in patients with hypertension and heart failure. Int J Gerontol. 2015;9(4):201–205.
   Web of Science ®Google Scholar
• Chazova IE, Zhernakova Yu V, Blinova NV, et al. The new angiotensin II receptor blocker Edarbi® as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders [in Russian]. Syst Hypertens. 2017; 14(3):28–35.
   Google Scholar
• Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006;45(2):120–159.
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435.
   PubMed Web of Science ®Google Scholar
• Liu H, Mao P, Wang J, et al. Azilsartan, an angiotensin II type 1 receptor blocker, attenuates tert-butyl hydroperoxide-induced endothelial cell injury through inhibition of mitochondrial dysfunction and anti-inflammatory activity. Neurochem Int. 2016;94:48–56.
   PubMed Web of Science ®Google Scholar
• Kajiya T, Ho C, Wang J, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011;29(12):2476–2483.
   PubMed Web of Science ®Google Scholar